Haemophilus influenzae Type B Infections - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Haemophilus influenzae Type B Infections - Pipeline Review, H2 2015', provides an overview of the Haemophilus influenzae Type B Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Haemophilus influenzae Type B Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Haemophilus influenzae Type B Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Haemophilus influenzae Type B Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Haemophilus influenzae Type B Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Haemophilus influenzae Type B Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Haemophilus influenzae Type B Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Haemophilus influenzae Type B Infections Overview 8
Therapeutics Development 9
Pipeline Products for Haemophilus influenzae Type B Infections - Overview 9
Pipeline Products for Haemophilus influenzae Type B Infections - Comparative Analysis 10
Haemophilus influenzae Type B Infections - Therapeutics under Development by Companies 11
Haemophilus influenzae Type B Infections - Therapeutics under Investigation by Universities/Institutes 12
Haemophilus influenzae Type B Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Haemophilus influenzae Type B Infections - Products under Development by Companies 16
Haemophilus influenzae Type B Infections - Products under Investigation by Universities/Institutes 17
Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development 18
Beijing Minhai Biotechnology Co., Ltd 18
Biological E. Limited 19
CSL Limited 20
Daiichi Sankyo Company, Limited 21
Indian Immunologicals Limited 22
LG Life Science LTD. 23
Nuron Biotech, Inc. (Inactive) 24
Panacea Biotec Limited 25
Sanofi Pasteur SA 26
Sinovac Biotech Ltd. 27
Zydus Cadila Healthcare Limited 28
Haemophilus influenzae Type B Infections - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
(diphtheria + pertussis (wholl cell) + tetanus + hepatitis B + Haemophilus influenza [serotype B]) (pentavalent) vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
(diphtheria + tetanus + pertussis (acellular) + Haemophilus influenza [serotype B] + polio) vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
(diphtheria + tetanus + pertussis (acellular) + Haemophilus influenza [serotype B]) vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
(diphtheria + tetanus + pertussis (whole cell) + Haemophilus influenzae [serotype B] + polio) (pentavalent) vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + poliomyelitis + Haemophilus influenzae [serotype B]) (hexavalent) vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(diphtheria + tetanus + pertussis (whole-cell) + Haemophilus influenzae [serotype B]) vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
(diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + Haemophilus influenzae [serotype B]) (pentavalent) vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + Haemophilus influenzae [serotype B]) vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C]) (7-valent) vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(diphtheria + tetanus+ pertussis (whole cell) + hepatitis B + Haemophilus influenzae [serotype B]) (pentavalent) vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
haemophilus influenza [serotype B] vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
haemophilus influenzae [serotype B] vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
haemophilus influenzae [serotype B] vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
haemophilus influenzae [serotype B] vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
haemophilus influenzae [serotype B] vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
NU-300 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PR-5I - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
VN-0105 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Haemophilus influenzae Type B Infections - Recent Pipeline Updates 56
Haemophilus influenzae Type B Infections - Dormant Projects 58
Haemophilus influenzae Type B Infections - Product Development Milestones 59
Featured News & Press Releases 59
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 59
Sep 26, 2013: Takeda Submits New Drug Application in Japan for TAK-816, a Haemophilus Influenzae type b vaccine 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for Haemophilus influenzae Type B Infections, H2 2015 9
Number of Products under Development for Haemophilus influenzae Type B Infections - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Number of Products under Investigation by Universities/Institutes, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Products under Investigation by Universities/Institutes, H2 2015 17
Haemophilus influenzae Type B Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015 18
Haemophilus influenzae Type B Infections - Pipeline by Biological E. Limited, H2 2015 19
Haemophilus influenzae Type B Infections - Pipeline by CSL Limited, H2 2015 20
Haemophilus influenzae Type B Infections - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 21
Haemophilus influenzae Type B Infections - Pipeline by Indian Immunologicals Limited, H2 2015 22
Haemophilus influenzae Type B Infections - Pipeline by LG Life Science LTD., H2 2015 23
Haemophilus influenzae Type B Infections - Pipeline by Nuron Biotech, Inc. (Inactive), H2 2015 24
Haemophilus influenzae Type B Infections - Pipeline by Panacea Biotec Limited, H2 2015 25
Haemophilus influenzae Type B Infections - Pipeline by Sanofi Pasteur SA, H2 2015 26
Haemophilus influenzae Type B Infections - Pipeline by Sinovac Biotech Ltd., H2 2015 27
Haemophilus influenzae Type B Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 28
Assessment by Monotherapy Products, H2 2015 29
Assessment by Combination Products, H2 2015 30
Number of Products by Stage and Target, H2 2015 32
Number of Products by Stage and Route of Administration, H2 2015 34
Number of Products by Stage and Molecule Type, H2 2015 36
Haemophilus influenzae Type B Infections Therapeutics - Recent Pipeline Updates, H2 2015 56
Haemophilus influenzae Type B Infections - Dormant Projects, H2 2015 58